Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Large-Scale Study Sheds Light on Rare Eye Disorders
Researchers have analyzed image and genomic data from the UK Biobank to find insights into rare diseases of the human eye. These include retinal dystrophies – a group of inherited disorders affecting the retina – which are also the leading…
Novartis CEO Denies Ophthalmology Unit Sell-off Rumors
At the J.P. Morgan Healthcare Conference, Novartis CEO Vas Narasimhan denied rumors that the pharmaceutical giant is planning to sell its respiratory and ophthalmology units altogether. The rumors, which have been circulating for several weeks, suggested that Novartis was looking…
Novartis Initiates Sale of Ophthalmology Assets
According to sources familiar with the matter, Novartis AG is kicking off the process of selling some of its ophthalmology assets in order to prune its portfolio and concentrate on other therapeutic areas, including hematology, immunology, solid tumors, neurology, and…
Bausch + Lomb Acquires Eye Drugs from Novartis
Bausch + Lomb has announced that it will acquire the dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Novartis. Xiidra is an eye drop without steroids that has received specific approval for treating the signs and symptoms of dry…
What Is Leber Congenital Amaurosis?
Leber Congenital Amaurosis (LCA) is a rare genetic disorder that affects the retina, the part of the eye responsible for sensing light and sending visual signals to the brain. It is a severe form of retinal dystrophy, which means that…
Dysphotopsia: Causes, Symptoms, Treatment | OBN
What Is Dysphotopsia? Dysphotopsia, a term often sending shivers down the spine of even the most experienced ophthalmologists, refers to a spectrum of visual disturbances that patients may experience following cataract surgery. It is derived from the Greek words ‘dys’…
Japan’s PMDA Approves Aurion Biotech’s NDA
Aurion Biotech announced that it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its pioneering cell therapy, VyznovaTM, designed for treating bullous keratopathy of the cornea. According to the company, this represents the world’s first…
VSY’s SVT Technology Secures Patent Grant in the US
Andreas C. Kühnel, Managing Director at VSY Biotechnology announced that the company’s innovative Sinusoidal Vision Technology (SVT®) has received its U.S. patent from the United States Patent and Trademark Office. This significant milestone is a testament to the company’s commitment…
Tiny Eye Implant: A Diabetes Treatment Option
In Sweden, researchers have created a microscale device designed for implantation in the eye, opening up new paths for cell-based treatments for conditions like diabetes. Developed by a team from KTH Royal Institute of Technology and Karolinska Institutet, this 3D-printed…
J. Martin Heur, MD, PhD, named chair of Department of Ophthalmology – keck.usc.edu
J. Martin Heur, MD, PhD, named chair of Department of Ophthalmology keck.usc.edu Source: Author: | Date: 2023-10-18 07:00:00 Source: Author: | Date: 2023-10-18 07:00:00